About Renovacor
Renovacor is a company based in Philadelphia (United States) founded in 2013 by Arthur Feldman was acquired by Rocket Pharma in September 2022. Renovacor has raised $11 million across 1 funding round from investors including Rocket Pharma, New Leaf Venture Partners and Novartis Venture Fund. Renovacor operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
- Headquarter Philadelphia, United States
- Founders Arthur Feldman
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
-$780.77 K (USD)-150048as on Dec 31, 2020
-
EBITDA
-$801.96 K (USD)-154123as on Dec 31, 2020
-
Total Equity Funding
$11 M (USD)
in 1 rounds
-
Latest Funding Round
$11 M (USD), Series A
Aug 14, 2019
-
Investors
Rocket Pharma
& 5 more
-
Employee Count
Not available
-
Acquired by
Rocket Pharma
(Sep 20, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Renovacor
Unlock access to complete
Unlock access to complete
Funding Insights of Renovacor
Renovacor has successfully raised a total of $11M through 1 strategic funding round. The most recent funding activity was a Series A round of $11 million completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Renovacor
Renovacor has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Rocket Pharma, New Leaf Venture Partners and Novartis Venture Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in innovative life science companies globally.
|
Locked | Locked | Locked | |
|
Seed-stage life sciences investments are made in the US.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Renovacor
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Renovacor
Investment portfolio details for Renovacor
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Renovacor
Detailed financials for Renovacor
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Renovacor Comparisons
Peer comparison for Renovacor
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Renovacor
Renovacor operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Drugs for CNS disorders are developed and advanced.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
Detailed competitors of Renovacor
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Renovacor
Complete news archive for Renovacor
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Renovacor
Renovacor was founded in 2013 and raised its 1st funding round 6 years after it was founded.
Renovacor is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Magdalene Cook is the current CEO of Renovacor.
Renovacor is a funded company, having raised a total of $11M across 1 funding round to date.
Renovacor was founded in 2013 in Philadelphia, United States, within the biotechnology sector. Emphasis is placed on drug development for cardiovascular and central nervous system disorders. BAG3-related gene therapies are pursued, including the candidate molecule REN-001, which remains in preclinical and research stages for cardiomyopathy and CNS indications. Operations center on advancing these therapies toward clinical applications.
Renovacor's top competitors include Jazz Pharmaceuticals, Neurocrine and Biohaven Pharmaceutical.
Renovacor has 6 investors. Key investors include Rocket Pharma, New Leaf Venture Partners, Novartis Venture Fund, Broadview Ventures, and BioAdvance.